Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.
Jeremy S. Abramson, MD, MMSc
Released: March 26, 2021

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:

  • Approved and Investigational Targeted Therapeutics for CLL
  • Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
  • Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
  • Treatment for Older Patients With Hodgkin Lymphoma


Jeremy S. Abramson, MD, MMSc
Associate Professor  
Department of Medicine  
Harvard Medical School  
Director, Center for Lymphoma  
Massachusetts General Hospital  
Boston, Massachusetts


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas

Elizabeth Brém, MD Christopher R. Flowers, MD, MS Released: June 21, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 17, 2022

Phase II trial shows high response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 chemotherapy in newly diagnosed FLT3-mutated AML, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings